Cancer-selective induction of apoptosis by leczyme

13Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Sialic acid-binding lectin (SBL) is a multi-functional protein that is isolated from oocytes of Rana catesbeiana. It has both lectin and ribonuclease (enzyme) properties, and therefore is called leczyme. We examined the anti-tumor effects of SBL and discovered that SBL has potential as a new type of anti-cancer drug. SBL causes a cancer-selective induction of apoptosis by multiple signaling pathways whereby RNA is its target. It is suggested that the mitochondrial pathway and endoplasmic reticulum stress-mediated pathway participate in SBL-induced signaling. The synergistic anti-tumor effects with other molecules, such as tumor necrosis factor-related apoptosis ligand and interferon ?, have been reported. In this study, we summarize the effects of SBL and focus on its cancer-selective apoptotic properties. In addition, we present a possible explanation for its cancer specificity. © 2014 Tatsuta, Sugawara.

Cite

CITATION STYLE

APA

Tatsuta, T., Sugawara, S., Takahashi, K., Ogawa, Y., Hosono, M., & Nitta, K. (2014). Cancer-selective induction of apoptosis by leczyme. Frontiers in Oncology. Frontiers Research Foundation. https://doi.org/10.3389/fonc.2014.00139

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free